Efficacy and safety of posaconazole for chronic pulmonary aspergillosis

Clinical Infectious Diseases

Volumn 51, Issue 12, 2010, Pages 1383-1391

  Felton, Timothy W ^a,c   Baxter, Caroline ^a,c   Moore, Caroline B ^a,c   Roberts, Stephen A ^a,b   Hope, William W ^a,c   Denning, David W ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIBODY; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACNE; ADULT; AGED; ANTIBODY TITER; ARTICLE; ASPERGILLUS; CHRONIC DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; KAPLAN MEIER METHOD; LETHARGY; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PSORIASIS; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; ASPERGILLUS; CHRONIC DISEASE; FEMALE; HUMANS; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PULMONARY ASPERGILLOSIS; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; SERUM; TREATMENT FAILURE; TREATMENT OUTCOME; TRIAZOLES;

EID: 78649834297     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657306     Document Type: Article

References (33)

1. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43(Suppl 1):S207-S238.
2. Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987; 92(3):505-508.
3. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2009; 14:e479-e482.
4. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax 1983; 38(8):572-578. (Pubitemid 13036985)
5. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37(Suppl 3):S265-S280.
6. Crosdale DJ, Poulton KV, Ollier WE, Thomson W, Denning DW. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis 2001; 184(5):653-656. (Pubitemid 32783560)
7. Vaid M, Kaur S, Sambatakou H, Madan T, Denning DW, Sarma PU. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007; 45(2):183-186. (Pubitemid 46294684)
8. Sambatakou H, Pravica V, Hutchinson IV, Denning DW. Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet 2006; 33(4):297-302.
9. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3):327-360. (Pubitemid 351265310)
10. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49(6):928-930.
11. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15(7):1068-1076.
12. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006; 52(5):e133-e137.
13. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010; 18(5):195-204.
14. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4):348-359. (Pubitemid 46148777)
15. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356(4):335-347.
16. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44(1):2-12.
17. Kaplan E, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958; 53(282):457-481.
18. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2009.
19. Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European Committee on antimicrobial susceptibility testing EUCAST. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clinical Microbiology and Infection 2008; 14(10):982-984.
20. Moore CB, Duddy NE, Denning DW, Hope WW. Development of a Bioassay for Posaconazole Blood Levels and its use in the Clinical Laboratory. In: Program and abstracts of the European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2008. Abstract P1351.
21. Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991; 46(11):839-841.
22. Caras WE, Pluss JL. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71(1):25-30. (Pubitemid 26021787)
23. De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 1988; 31(9):476-485.
24. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23(3 Pt 2):607-614.
25. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112(2):541-548.
26. Tsubura E. [Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group]. Kekkaku 1997; 72(10):557-564.
27. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131(5):1435-1441.
28. Saito Y, Ogawa K, Kurashima A, et al. A first randomized trial comparing micafungin and voriconazole for chronic necrotizing pulmonary aspergillosis in Japan. In: Program and abstracts of the 50th International Conference on Antimicrobial Agents and Chemotherapy; Boston, MA, 12-15 September, 2009. Abstract M-1048.
29. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119(6):527 e17-e24.
30. Izumikawa K, Ohtsu Y, Kawabata M, et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007; 45(3):273-278.
31. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36(5):372-379. (Pubitemid 38967695)
32. Yasuda S, Ohnishi R, Suzuki T, Sano K, Kato T. [Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole]. Nihon Kokyuki Gakkai Zasshi 2009; 47(11):985-990.
33. Philippe B, Cadranel J, Hennequin C, et al. Voriconazole (VORI) for proven chronic pulmonary aspergillosis (CPA): a prospective multicenter trial. In: Program and abstracts of the European Respiratory Society Annual Congress; Vienna, Austria; 12-16 September, 2009. Abstract P2458.